Ensign Peak Advisors
CYCN icon

Ensign Peak Advisors’s Cyclerion Therapeutics CYCN Stock Holding History

Ensign Peak Advisors’s Portfolio CYCN Stock Details CYCN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q4 		– Sell
-3,460
Closed -$420K – 1863
2020
Q3 		$420K Buy
3,460
+2,113
+157% +$242K ﹤0.01% 1571
2020
Q2 		$159K Hold
1,347
– – ﹤0.01% 1602
2020
Q1 		$71K Buy
+1,347
New +$96.1K ﹤0.01% 1588

Other funds holding CYCN

SPC
Slate Path Capital New York $6.73B AUM 95.97% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
MP
MFN Partners Boston, Massachusetts $4.77B AUM 72.29% 1-Year Est. Return
AG
Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Ensign Peak Advisors's CYCN Position: Q4 2020 in Review

Ensign Peak Advisors sold out of Cyclerion Therapeutics (CYCN) in Q4 2020, closing a stake of 3,460 shares — an estimated $420K sold.

Ensign Peak Advisors first reported a position in CYCN in Q1 2020 and held it in 3 quarters. The position peaked at $420K in Q3 2020. 73 funds tracked by Wall St. Rank hold CYCN as of Q4 2020.

  • Ensign Peak Advisors reported no remaining Cyclerion Therapeutics position as of Q4 2020 after selling out during the quarter.
  • Ensign Peak Advisors sold 3,460 Cyclerion Therapeutics shares in Q4 2020, an estimated $420K.
  • Ensign Peak Advisors first reported a position in Cyclerion Therapeutics in Q1 2020 and held it in 3 quarters.
  • Ensign Peak Advisors's Cyclerion Therapeutics position peaked at $420K in Q3 2020.
  • 73 funds tracked by Wall St. Rank held Cyclerion Therapeutics as of Q4 2020.

Based on Ensign Peak Advisors's 13F filing for Q4 2020, filed 12 Feb 2021.